Advancements in the efficacy and increased utilization of synergistic anti-platelet agents, anticoagulant therapies, and invasive risk<unk> ratification in high-risk patients with<unk><unk>  and<unk> -ST-segment<unk><unk><unk>  (NSTEMI) has led to a 40% decrease in mortality from coronary artery disease (CAD) over the preceding 20 years. The advanced management of NSTEMI minimizes ischemic events; however the paradigm is that it also increases the risk of<unk>  and necessitation for blood<unk> . Recent analyses and randomized controlled trials demonstrate an independent association between<unk> <unk> , blood<unk> s, and poor outcomes among NSTEMI patients. Clinical trials of antithrombotic therapies associated with decreased<unk> <unk>  have demonstrated improvements in short-term and long-term survival.
Unstable angina / non ST elevation myocardial infarction complications of bleeding and transfusion
PCI complications: thrombocytopenia
Congestive heart failure and thrombosis
Cardiac disease in pregnancy and repaired congenital heart disease
Diabetes mellitus and pregnancy
Deep vein thrombosis special scenario pregnancy
Cardiac disease in pregnancy and peripartum cardiomyopathy
Cardiac disease in pregnancy and congenital heart disease